Phenotypic Cellular Assays Relating to Gastroenterology

Takeda Pharmaceutical Company Ltd. has developed a curated selective kinase inhibitor library capable of inhibiting more than 130 kinases. To foster partnerships based on complementary strengths with academia they seek researchers with access to cell-based phenotypic assays related to Gastroenterology. Successful applicants will receive up to 15,000USD for project costs (exact funding size will be at Takeda's discretion) to test the library in their own laboratory. Additionally, all academics given access to the library will be able to utilize their results (i.e the kinase inhibitory profile and the chemical structures of up to 3 hit molecules) to investigate novel pathways to regulate the phenotype, publish them (after permission from Takeda), and potentially be offered further collaboration opportunities by Takeda.

Selective Kinase Inhibitor Tools (SKIT) library:

An ultra-high-throughput assessment of Takeda's proprietary compounds as well as literature-known compounds led to the selection of over 200 compounds targeting over 130 kinases with the following profiles:

1. **High potency and selectivity for their primary target** (IC50<50 nM)
2. **Applicability to cellular based assays** (good solubility, cell-permeable and low cytotoxicity)
3. **Uniqueness** (novel target and includes Takeda original chemical structures)

Academic groups of interest:

Those with access to phenotypic cellular assays which satisfy the following criteria:

- Plausibly represents **gastrointestinal motility or liver fibrosis disorders** *(details are in the link below)*
- Preferably human-derived cells or equivalent (e.g. patient-derived iPS)
- Preferably applicable for drug discovery

Applications accepted from European and US institutions only. A research proposal template can be found [here](mailto:discover@in-part.co.uk) for submissions.

Opportunities sought

- Academics and expertise
- Research groups

Submissions

Please submit relevant opportunities, or questions, to [discover@in-part.co.uk](mailto:discover@in-part.co.uk)

Using subject header: **Gastroenterology**

Before: **1st March 2019**

This call is being undertaken by the SKIT Open Innovation team at Takeda Pharmaceutical Company Ltd. Takeda hope that their proprietary compounds will help academics further the development of their research and generate new scientific insights for therapeutic intervention.